{
    "nctId": "NCT00963729",
    "briefTitle": "Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery",
    "officialTitle": "A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal Patients With Primary Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 756,
    "primaryOutcomeMeasure": "Feasibility of patient recruitment (pilot)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically proven primary invasive breast cancer that is thought to be suitable for neoadjuvant treatment\n\n  * No cytological proof of malignancy only\n  * T2 tumor or greater (\u2265 20 mm by ultrasound) or any T stage with nodal disease \u2265 20 mm diameter on ultrasound assessment\n  * No evidence of distant metastatic disease as disclosed by bone scan, liver, and chest imaging\n* Definite indication for neoadjuvant and adjuvant chemotherapy\n* Primary tumor amenable to biopsy\n* No inoperable disease that is judged very unlikely to be rendered operable by neoadjuvant treatment\n* No inflammatory breast cancer\n* No bilateral invasive breast cancer\n* HER-2 positivity is NOT an exclusion criterion in the feasibility (pilot) study\n* Estrogen receptor (ER) positive tumor\n\n  * No ER-poor disease as defined locally (e.g., H-score \\< 100, Allred 3/4/5)\n  * Allred 6/7/8, H-score H \u2265100 allowed\n\nPATIENT CHARACTERISTICS:\n\n* Postmenopausal, meeting 1 of the following criteria:\n\n  * Over 12 months since last menstrual period\n  * Postmenopausal gonadotrophin levels (luteinizing hormone or follicle-stimulating hormone levels above local criteria)\n  * Postmenopausal estradiol levels below local criteria\n  * Prior bilateral oophorectomy\n  * Menopause induced by gonadotrophin-releasing hormone not allowed\n* WHO performance status 0 or 1\n* WBC \u2265 3.0 \u00d7 10\\^9/L\n* ANC \u2265 1.5 \u00d7 10\\^9/L\n* Platelets \u2265 100 \u00d7 10\\^9/L\n* Hemoglobin \\> 9 g/dL\n* AST/ALT \u2264 1.5 times upper limit of normal (ULN)\n* Serum bilirubin \u2264 1.5 times ULN\n* Alkaline phosphatase \u2264 1.5 times ULN\n* Serum creatinine \u2264 1.5 times ULN\n* No active, uncontrolled infection\n* No malignancy within the past 10 years except for basal cell carcinoma or cervical carcinoma in situ\n\n  * Treatment for previous malignancy confined to resection alone\n* No concomitant medical, psychiatric, or geographic problems that might prevent completion of treatment or follow-up\n* No known severe hypersensitivity to aromatase inhibitors\n* No contraindication to receiving aromatase inhibitors (clinical evidence or recorded history of osteoporosis)\n* No other serious illness or medical condition including any of the following:\n\n  * Congestive heart failure or unstable angina pectoris\n  * Myocardial infarction within the past year\n  * Uncontrolled hypertension or high-risk uncontrolled arrhythmias\n  * History of significant neurologic or psychiatric disorders, including psychotic disorders, dementia, or seizures, that would prohibit the understanding and giving of informed consent\n  * Active peptic ulcer\n  * Unstable diabetes mellitus\n* No definite contraindications for the use of corticosteroids\n* No contraindication to receiving combination anthracycline/taxane chemotherapy\n* Willing to undergo repeat biopsies\n\nPRIOR CONCURRENT THERAPY:\n\n* No hormone replacement therapy within 4 weeks of starting treatment\n* No chronic oral treatment with corticosteroids unless initiated \\> 6 months prior to study entry and at low dose (\u2264 20 mg methylprednisolone or equivalent)\n* No concurrent warfarin or heparin therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}